卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌的II期CLAP研究
这项多中心、开放标签、单臂II期研究评估了卡瑞利珠单抗联合阿帕替尼在至少一线系统治疗进展后的晚期宫颈癌患者中的疗效与安全性。联合方案显示出有前景的抗肿瘤活性且毒性可控。
要点
- 卡瑞利珠单抗联合阿帕替尼在晚期宫颈癌中ORR达55.6%,中位PFS为8.8个月。
- 治疗相关3/4级不良事件发生率为71.1%,常见为高血压、贫血和乏力。
- 结论需更大规模随机对照试验验证。
核心结论
- 卡瑞利珠单抗联合阿帕替尼在晚期宫颈癌患者中具有有前景的抗肿瘤活性和可控的毒性。
研究设计与样本
- 患者接受卡瑞利珠单抗200 mg每2周一次联合阿帕替尼250 mg每日一次。
- 主要终点为研究者按RECIST 1.1评估的客观缓解率。
主要发现
- 客观缓解率为55.6%(95% CI 40.0%至70.4%),包括2例完全缓解和23例部分缓解。
- 中位无进展生存期为8.8个月(95% CI 5.6个月至不可估计),中位缓解持续时间和中位总生存期未达到。
- 治疗相关3/4级不良事件发生率为71.1%,最常见为高血压(24.4%)、贫血(20.0%)和乏力(15.6%)。
- 常见潜在免疫相关不良事件包括1-2级甲状腺功能减退(22.2%)和反应性毛细血管内皮增生(8.9%)。
临床怎么用
- 对于至少一线系统治疗进展的晚期宫颈癌患者,卡瑞利珠单抗联合阿帕替尼可作为候选方案,但需关注高血压、贫血等毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Camrelizumab is an antibody against programmed death protein 1. We assessed the activity and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, in patients with advanced cervical cancer. METHODS: This multicenter, open-label, single-arm, phase II study enrolled patients with advanced cervical cancer who progressed after at least one line of systemic therapy. Patients received camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day. The primary end point was objective response rate (ORR) assessed by investigators per RECIST version 1.1. Key secondary end points were progression-free survival (PFS), overall survival (OS), duration of response, and safety. RESULTS: Forty-five patients were enrolled and received treatment. Median age was 51.0 years (range, 33-67 years), and 57.8% of patients had previously received two or more lines of chemotherapy for recurrent or metastatic disease. Ten patients (22.2%) had received bevacizumab. Median follow-up was 11.3 months (range, 1.0-15.5 months). ORR was 55.6% (95% CI, 40.0% to 70.4%), with two complete and 23 partial responses. Median PFS was 8.8 months (95% CI, 5.6 months to not estimable). Median duration of response and median OS were not reached. Treatment-related grade 3 or 4 adverse events (AEs) occurred in 71.1% of patients, and the most common AEs were hypertension (24.4%), anemia (20.0%), and fatigue (15.6%). The most common potential immune-related AEs included grade 1-2 hypothyroidism (22.2%) and reactive cutaneous capillary endothelial proliferation (8.9%). CONCLUSION: Camrelizumab plus apatinib had promising antitumor activity and manageable toxicities in patients with advanced cervical cancer. Larger randomized controlled trials are warranted to validate our findings.
引用
- Lan C, Shen J, Wang Y, et al. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. J Clin Oncol. 2020. PMID: 33052760. doi:10.1200/JCO.20.01920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。